Athersys, Inc. (NASDAQ:ATHX) Short Interest Down 7.9% in October

Share on StockTwits

Athersys, Inc. (NASDAQ:ATHX) saw a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 12,310,000 shares, a decrease of 7.9% from the September 30th total of 13,370,000 shares. Approximately 8.7% of the company’s stock are short sold. Based on an average daily volume of 468,300 shares, the days-to-cover ratio is currently 26.3 days.

Shares of ATHX stock opened at $1.39 on Friday. Athersys has a one year low of $1.20 and a one year high of $2.15. The company has a market capitalization of $211.50 million, a price-to-earnings ratio of -7.72 and a beta of 0.32. The company’s 50-day moving average is $1.33 and its 200 day moving average is $1.49.

Athersys (NASDAQ:ATHX) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.08) EPS for the quarter, hitting analysts’ consensus estimates of ($0.08). Athersys had a negative net margin of 458.03% and a negative return on equity of 131.22%. The company had revenue of ($0.36) million for the quarter, compared to analysts’ expectations of $1.51 million. As a group, analysts anticipate that Athersys will post -0.31 EPS for the current year.

ATHX has been the topic of several recent analyst reports. ValuEngine raised shares of Athersys from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Dawson James initiated coverage on shares of Athersys in a research report on Monday, August 26th. They set a “buy” rating and a $11.00 price objective on the stock. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $6.92.

In related news, COO William Lehmann, Jr. sold 30,000 shares of the stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $1.44, for a total transaction of $43,200.00. Following the sale, the chief operating officer now directly owns 542,196 shares of the company’s stock, valued at approximately $780,762.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 15.31% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Bank of New York Mellon Corp grew its holdings in Athersys by 6.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 373,082 shares of the biopharmaceutical company’s stock valued at $627,000 after buying an additional 23,862 shares in the last quarter. NEXT Financial Group Inc grew its holdings in Athersys by 23.8% during the 2nd quarter. NEXT Financial Group Inc now owns 145,500 shares of the biopharmaceutical company’s stock valued at $244,000 after buying an additional 28,000 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors purchased a new stake in Athersys during the 2nd quarter valued at approximately $25,000. Cambridge Investment Research Advisors Inc. grew its holdings in Athersys by 133.2% during the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 37,550 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 21,450 shares in the last quarter. Finally, Wells Fargo & Company MN grew its holdings in Athersys by 15.5% during the 2nd quarter. Wells Fargo & Company MN now owns 253,063 shares of the biopharmaceutical company’s stock valued at $426,000 after buying an additional 33,985 shares in the last quarter. 21.50% of the stock is owned by institutional investors and hedge funds.

About Athersys

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.

Read More: What is a good rate of return for a mutual fund?

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Arena Pharmaceuticals, Inc.  Given Average Rating of “Hold” by Brokerages
Arena Pharmaceuticals, Inc. Given Average Rating of “Hold” by Brokerages
MASTERNET Reaches Market Capitalization of $4,359.00
MASTERNET Reaches Market Capitalization of $4,359.00
Storj  Tops 1-Day Trading Volume of $2.48 Million
Storj Tops 1-Day Trading Volume of $2.48 Million
SUEZ/ADR  Receives Consensus Recommendation of “Hold” from Brokerages
SUEZ/ADR Receives Consensus Recommendation of “Hold” from Brokerages
Nanometrics Incorporated  Receives $40.50 Average PT from Analysts
Nanometrics Incorporated Receives $40.50 Average PT from Analysts
TTC Price Tops $0.0254 on Major Exchanges
TTC Price Tops $0.0254 on Major Exchanges


© 2006-2019 Ticker Report